

ASX Announcement

19 March 2026

Late Lodgement of Appendix 3Y

OncoSil Medical Ltd (ASX: OSL) (“OncoSil” or “the Company”) provides the following Appendix 3Y for CEO and Managing Director Mr Nigel Lange.

The Appendix 3Y includes changes resulting from the lapsing of Performance Rights and Employee Loan Funded Shares which have been cancelled, having lapsed in accordance with their terms and conditions.

In relation to the late lodgement of the Appendices 3Y, the Company advises the following:

1. The Appendix 3Y was lodged late due to an administrative oversight following the lapse of the Performance Rights and Employee Loan Funded Shares.
2. The Company and the Directors are aware of their obligations under ASX Listing Rules 3.19A and 3.19B to provide the necessary information to the Company to meet its disclosure requirements. The Company has a Securities Trading Policy in place which sets out Directors requirements to notify the Company of changes in interests.
3. The Company considers that the late lodgement is an isolated incident and believes that its current practices are adequate to ensure compliance with the ASX Listing Rules.

This announcement has been authorised for release by the Board of Directors of OncoSil Medical Ltd.

For further information, please contact:

<p>Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043</p>	<p>Mr. Tim Luscombe Company Secretary E: tim.luscombe@bio101.com T: +61 429 707 079</p>	<p>Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338</p>
--	---	--

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical’s mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European

Union, United Kingdom, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oncosil Medical Limited (ASX: OSL)
ABN	89 113 824 141

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Nigel Lange
Date of last notice	2 December 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	17 March 2026, 21 October 2025 and 11 December 2025
No. of securities held prior to change	Shares: 18,046 Options: 116,657 Performance rights: 242,029
Class	Shares Options (exercise price \$0.90, expiry 30 June 2027) Performance rights
Number acquired	Shares: 103,039 Options: 73,530
Number disposed	Shares: 14,296 Performance rights: 7,105

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Employee Loan Funded Shares and Performance Rights lapsed for Nil consideration.</p> <p>Shares issued for \$0.68 per Share pursuant to placement participation. Options issued for nil cash consideration, as free-attaching on the basis of one (1) Option for every Share issued under the placement.</p> <p>Shares issued for \$1.50 per Share in lieu of cash salary.</p>
<p>No. of securities held after change</p>	<p>Shares: 106,789 Options: 190,187 Performance rights: 234,924</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Lapse of Employee Loan Funded Shares and Performance Rights.</p> <p>Issue of securities pursuant to placement participation, as approved by shareholders at the 12 March 2026 Extraordinary General Meeting.</p> <p>Issue of Shares in lieu of cash salary, as approved by shareholders at the 12 March 2026 Extraordinary General Meeting.</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p>Detail of contract</p>	<p>N/A</p>
<p>Nature of interest</p>	<p>N/A</p>
<p>Name of registered holder (if issued securities)</p>	<p>N/A</p>
<p>Date of change</p>	<p>N/A</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.